04 · Alert System
Recalls, enforcement actions, and viral ingredient spikes requiring immediate consultant awareness. Red requires action, amber requires monitoring, green flags opportunity.
Last reviewed July 2026
3 red alerts activeXlear sued the FTC after the agency dropped its 2021 case over the company's sinus rinse marketing, asking a court to bar FTC from requiring clinical-trial-level substantiation for health claims and to shift the burden onto government to disprove claims instead. The Alliance for Natural Health filed a parallel petition seeking withdrawal of FTC's 2022 substantiation guidance. A ruling against FTC would remove the clinical-evidence requirement for health claims industry-wide.
Consumer search and social signals also inform velocity rating.
FDA and CDC traced the outbreak to contaminated moringa leaf powder supplied to multiple brands. The case now totals 119 illnesses and 32 hospitalizations across 36 states since August 2025. FDA had declared the outbreak over on March 17, 2026, but reopened the investigation after additional cases surfaced in late June. Moringa leaf powder is implicated as a cross-brand contamination source.
Consumer search and social signals also inform velocity rating.
FTC filed a contempt motion and suit against Amare Global over unsubstantiated health claims made for both children's and adult supplement products. The action signals continued FTC willingness to pursue enforcement even as the Xlear case tests the underlying substantiation standard. Brand clients should treat this as a reminder that current enforcement posture remains active.
Consumer search and social signals also inform velocity rating.
FDA sent letters to manufacturers reinstating NMN's status as a legal dietary ingredient. Companies without a filed New Dietary Ingredient Notification remain exposed unless sourcing from a supplier that already filed one.
Consumer search and social signals also inform velocity rating.
Social-driven demand for methylene blue as a nootropic is outrunning safety data. No human safety data exists to support the cognitive claims circulating online. Treat this as a watch item for liability exposure, not a formulation opportunity.
Tier 3 signal. Social and consumer-trend monitoring; no primary source URL.
A magnesium gummy recall for undeclared melatonin points to a cross-contamination and formulation control issue relevant to any client co-manufacturing gummies. Brands using shared gummy manufacturing lines should confirm supplier controls against cross-contamination.
Tier 2 signal. General recall press coverage; no single primary source URL provided this edition.
FDA is exercising enforcement discretion on DSHEA disclaimer placement ahead of formal rulemaking. Clients redesigning labels this cycle can consolidate disclaimer placement now, cutting packaging costs without waiting for the final rule.
Consumer search and social signals also inform velocity rating.
Postbiotics are gaining formulation flexibility into shelf-stable formats, opening new product categories such as bars and beverages that live probiotics could never enter. This is a formulation opportunity, not just a claims one.
Consumer search and social signals also inform velocity rating.
"The regulatory and claim environment in dietary supplements has never been more consequential. Getting the evidence framing right is as important as the formulation itself."
Schedule a consultation →